Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at RODMAN&RENSHAW

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) was upgraded by equities research analysts at RODMAN&RENSHAW to a "strong-buy" rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

A number of other equities analysts also recently issued reports on the stock. TD Cowen began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a "buy" rating for the company. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $48.00 price target for the company. Cantor Fitzgerald began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an "overweight" rating for the company. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a "buy" rating and a $47.00 price target for the company. Finally, Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $43.33.

Bicara Therapeutics Price Performance

BCAX stock traded down $1.42 during trading on Tuesday, reaching $23.77. The company had a trading volume of 371,254 shares, compared to its average volume of 379,802. Bicara Therapeutics has a 52 week low of $18.33 and a 52 week high of $28.09.

Insider Activity

In other news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business's stock in a transaction dated Monday, September 16th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the acquisition, the director now directly owns 4,303,418 shares in the company, valued at $77,461,524. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business's stock in a transaction dated Monday, September 16th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the acquisition, the director now directly owns 4,303,418 shares in the company, valued at $77,461,524. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder James E. Flynn purchased 70,000 shares of the business's stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the acquisition, the insider now owns 897,587 shares of the company's stock, valued at approximately $16,156,566. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.